|
WO2005045034A2
(en)
*
|
2003-10-23 |
2005-05-19 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED TREATMENT OF PARKINSON DISEASE USING SHORT INTERERING NUCLEIC ACID (siNA)
|
|
WO2006039253A2
(en)
*
|
2004-09-29 |
2006-04-13 |
Children's Memorial Hospital |
Sirna-mediated gene silencing of alpha synuclein
|
|
EP2311967B1
(en)
|
2005-10-20 |
2017-09-20 |
UniQure IP B.V. |
Improved AAV vectors produced in insect cells
|
|
KR101589259B1
(ko)
|
2006-06-21 |
2016-02-01 |
유니큐어 아이피 비.브이. |
곤충세포 내 ａａｖ의 생산에 유용한 ａａｖ-ｒｅｐ78의 번역을 위한 변형된 개시 코돈을 갖는 벡터
|
|
SI3093345T1
(sl)
|
2007-07-26 |
2019-08-30 |
Uniqure Ip B.V. |
Bakulovirusni vektorji, ki vsebujejo ponavljajoča kodirna zaporedja z različnimi kodonskimi preferencami
|
|
WO2009079399A2
(en)
*
|
2007-12-14 |
2009-06-25 |
Alnylam Pharmaceuticals, Inc. |
Method of treating neurodegenerative disease
|
|
EP3257937B1
(en)
|
2008-02-19 |
2022-08-03 |
uniQure IP B.V. |
Optimisation of expression of parvoviral rep and cap proteins in insect cells
|
|
WO2010129791A1
(en)
*
|
2009-05-06 |
2010-11-11 |
University Of Medicine And Dentistry Of New Jersey |
Rna targeting in alpha-synucleinopathies
|
|
WO2011122950A1
(en)
|
2010-04-01 |
2011-10-06 |
Amsterdam Molecular Therapeutics (Amt) Ip B.V. |
Monomeric duplex aav vectors
|
|
HRP20182039T1
(hr)
*
|
2010-04-23 |
2019-02-08 |
Cold Spring Harbor Laboratory |
NOVE STRUKTURNO DIZAJNIRANE MOLEKULE shRNA
|
|
CA3077910A1
(en)
*
|
2010-11-17 |
2012-05-24 |
Ionis Pharmaceuticals, Inc. |
Modulation of alpha synuclein expression
|
|
PT2744895E
(pt)
|
2011-09-08 |
2016-02-08 |
Uniqure Ip Bv |
Remoção de vírus contaminantes de preparações de aav
|
|
AU2015370903B2
(en)
|
2014-12-24 |
2021-06-17 |
Uniqure Ip B.V. |
RNAi induced huntingtin gene suppression
|
|
BR112020006671A2
(pt)
*
|
2017-10-03 |
2020-12-01 |
Prevail Therapeutics, Inc. |
terapias genéticas para distúrbios lisossômicos
|
|
EP3830265A1
(en)
*
|
2018-08-03 |
2021-06-09 |
Genzyme Corporation |
Variant rnai against alpha-synuclein
|
|
WO2020104295A1
(en)
*
|
2018-11-19 |
2020-05-28 |
Uniqure Ip B.V. |
Rnai induced reduction of ataxin-3 for the treatment of spinocerebellar ataxia type 3
|
|
CA3119721A1
(en)
*
|
2018-11-19 |
2020-05-28 |
Uniqure Ip B.V. |
A companion diagnostic to monitor the effects of gene therapy
|
|
WO2021113270A1
(en)
*
|
2019-12-02 |
2021-06-10 |
Shape Therapeutics Inc. |
Therapeutic editing
|